25 NOVEMBER 2024, BUSAN, SOUTH KOREA – This statement is delivered on behalf of IFPMA, GSCF, and IGBA, who collectively represent innovative, generic, and biosimilars pharmaceutical companies, as well as consumer healthcare manufacturers.
14 NOVEMBER 2024, GENEVA – We support a UN instrument to end plastics pollution through a harmonized, global approach that also prioritizes patient safety and safeguards access to medicinal and medical products.
In the week ahead, the International Generic and Biosimilar medicines Association (IGBA) will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines, and focus on the importance of advancing access to these essential therapies.
- AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)
- IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)
- IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)
- IGBA Welcomes update to ICH M7 on Assessment and Control of Nitrosamine Impurities (June 2024)
